MacroGenics (MGNX) Competitors

Epizyme (NASDAQ:EPZM) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability.

Which has preferable valuation & earnings, EPZM or MGNX?

MacroGenics has higher revenue and earnings than Epizyme. MacroGenics is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Epizyme	$37.43M	6.61	-$251.12M	-$1.72	-0.85
MacroGenics	$139.77M	1.60	-$9.06M	-$1.58	-2.26

Do analysts rate EPZM or MGNX?

MacroGenics has a consensus price target of $7.63, suggesting a potential upside of 113.59%. Given MacroGenics' stronger consensus rating and higher probable upside, analysts clearly believe MacroGenics is more favorable than Epizyme.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Epizyme	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MacroGenics	0 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.36

Is EPZM or MGNX more profitable?

MacroGenics has a net margin of -69.07% compared to Epizyme's net margin of -391.90%. MacroGenics' return on equity of -89.42% beat Epizyme's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Epizyme	-391.90%	-2,459.33%	-69.74%
MacroGenics	-69.07%	-89.42%	-38.57%

Do institutionals and insiders hold more shares of EPZM or MGNX?

76.5% of Epizyme shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 23.4% of Epizyme shares are held by insiders. Comparatively, 11.3% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, EPZM or MGNX?

Epizyme has a beta of -0.41, suggesting that its stock price is 141% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500.

Does the media favor EPZM or MGNX?

In the previous week, MacroGenics had 10 more articles in the media than Epizyme. MarketBeat recorded 10 mentions for MacroGenics and 0 mentions for Epizyme. MacroGenics' average media sentiment score of 0.93 beat Epizyme's score of 0.22 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Overall Sentiment
Epizyme	Neutral
MacroGenics	Positive

Does the MarketBeat Community prefer EPZM or MGNX?

Epizyme received 51 more outperform votes than MacroGenics when rated by MarketBeat users. However, 62.28% of users gave MacroGenics an outperform vote while only 60.61% of users gave Epizyme an outperform vote.

Company	Underperform	Outperform
Epizyme	Outperform Votes 477 60.61%	Underperform Votes 310 39.39%
MacroGenics	Outperform Votes 426 62.28%	Underperform Votes 258 37.72%

Summary

MacroGenics beats Epizyme on 15 of the 19 factors compared between the two stocks.